Inositol nicotinate

background

Inositol nicotinate, also known as inositol hexaniacinate, consists of six nicotinic acid (niacin) molecules crossed-linked with an inositol molecule. Inositol nicotinate is a form of niacin (vitamin B3) which may decrease flushing, compared to niacin. Inositol nicotinate has been in use in Europe for over 30 years as a no-flush form of niacin.
Good scientific evidence supports the use of inositol nicotinate for peripheral artery disease. Inositol nicotinate has also been studied as a treatment for cerebral ischemia (lack of adequate blood flow to the brain), high cholesterol, high blood pressure, Raynaud's disease, and necrobiosis lipoidica (a skin condition associated with diabetes).

Related Terms

Hexanicit®, hexanicotinoyl inositol, Hexopal®, inositol hexaniacinate, inositol hexanicotinate, inositol niacinate, m-inositol nicotinate, meso-inositol, meso-inositol hexanicotinate, niacin, niacinamide, nicotinamide, nicotinic acid, no-flush niacin, vitamin B3.
Note: Inositol nicotinate consists of six nicotinic acid (niacin) molecules linked with an inositol molecule. When taken by mouth, inositol nicotinate is broken down into nicotinic acid (niacin) and inositol. Therefore, although inositol nicotinate may produce similar effects and adverse effects as niacin, only those effects and adverse effects specific to inositol nicotinate are included in this monograph.

evidence table

These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider.
 
Peripheral artery disease (Grade: B)
Inositol nicotinate may have beneficial effects in patients with peripheral artery disease. More studies are needed to make any conclusions in this area.
Cerebral ischemia (lack of adequate blood flow to the brain) (Grade: C)
Limited research suggests that inositol nicotinate may have beneficial effects in patients with cerebral ischemia. More studies are needed to make any conclusions in this area.
High cholesterol (Grade: C)
Limited research suggests that inositol nicotinate may have beneficial effects in patients with high cholesterol. Additional research is needed before a conclusion can be made.
High blood pressure (Grade: C)
Studies examining the effects of inositol nicotinate alone on high blood pressure are currently lacking. Further research on inositol nicotinate alone for this use is needed.
Raynaud's disease (Grade: C)
Limited research suggests that inositol nicotinate may have beneficial effects in patients with Raynaud's disease. Additional research is needed in this area.
Skin disorders (necrobiosis lipoidica) (Grade: C)
Necrobiosis lipoidica is an inflammatory disorder associated with diabetes mellitus. The cause is unknown and there is a lack of traditional therapies. Additional research is needed to determine if inositol nicotinate may be effective in the treatment of this condition.